Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics
Listed as NCT01001468, this PHASE2 trial focuses on Active Plaque Psoriasis and remains completed. Sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics, it has been updated 7 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vascular Biogenics Ltd. operating as VBL Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Berlin, Germany , Boston, United States , Dülmen, Germany , Düsseldorf, Germany , Frankfurt, Germany , Haverhill (Boston), United States , Kiel, Germany , Mahlow, Germany , Mainz, Germany , New York, United States and 4 more locations